Tags

Type your tag names separated by a space and hit enter

Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited.
Pharmacol Biochem Behav. 2002 Nov; 73(4):911-9.PB

Abstract

This study examined the effects of Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and the CB1 antagonist SR-141716 on open-field behaviors in male Sprague-Dawley rats. Animals were examined after administration of Delta(9)-THC alone (dose range: 0.3-5.6 mg/kg), SR-141716 alone (dose range: 1-5.6 mg/kg) and the two drugs in combination; injections were given intraperitoneally 30 min prior to testing. There was a dose-related suppression of ambulation (horizontal activity) and rearing (vertical activity) after Delta(9)-THC administration. Co-administration of SR-141716 counteracted this suppression; however, antagonism was only partial for rearing. Interestingly, 1 mg/kg SR-141716 was as effective as 3 and 5.6 mg/kg SR-141716 in this antagonist action. Increasing doses of Delta(9)-THC produced an increase in circling behavior; latency to leave the starting area in the center of the field was significantly elevated by 5.6 mg/kg Delta(9)-THC. Those effects were completely blocked by SR-141716. Grooming and scratching showed a dose-related increase following administration of SR-141716 (1-5.6 mg/kg), which were only partially blocked by co-administration of Delta(9)-THC (3 and 5.6 mg/kg). When given alone, only the highest dose of SR-141716 (5.6 mg/kg) depressed ambulation; rearing and latency were not significantly changed, and circling was absent. Differences in the number of vocalizations, urination and defecation generally did not differ clearly among the treatment conditions. These results may show that SR-141716 is acting as (i) an inverse agonist and/or (ii) that the endogenous cannabinoid system is tonically active under certain conditions.

Authors+Show Affiliations

Temple University, Department of Psychology, 265-67 Weiss Hall, 1701 North 13th Street, Philadelphia, PA 19122, USA. tjarbe@astro.temple.eduNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, U.S. Gov't, P.H.S.

Language

eng

PubMed ID

12213538

Citation

Järbe, Torbjörn U C., et al. "Interactions Between the CB1 Receptor Agonist Delta 9-THC and the CB1 Receptor Antagonist SR-141716 in Rats: Open-field Revisited." Pharmacology, Biochemistry, and Behavior, vol. 73, no. 4, 2002, pp. 911-9.
Järbe TU, Andrzejewski ME, DiPatrizio NV. Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacol Biochem Behav. 2002;73(4):911-9.
Järbe, T. U., Andrzejewski, M. E., & DiPatrizio, N. V. (2002). Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. Pharmacology, Biochemistry, and Behavior, 73(4), 911-9.
Järbe TU, Andrzejewski ME, DiPatrizio NV. Interactions Between the CB1 Receptor Agonist Delta 9-THC and the CB1 Receptor Antagonist SR-141716 in Rats: Open-field Revisited. Pharmacol Biochem Behav. 2002;73(4):911-9. PubMed PMID: 12213538.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited. AU - Järbe,Torbjörn U C, AU - Andrzejewski,Matthew E, AU - DiPatrizio,Nicholas V, PY - 2002/9/6/pubmed PY - 2003/3/5/medline PY - 2002/9/6/entrez SP - 911 EP - 9 JF - Pharmacology, biochemistry, and behavior JO - Pharmacol Biochem Behav VL - 73 IS - 4 N2 - This study examined the effects of Delta(9)-tetrahydrocannabinol (Delta(9)-THC) and the CB1 antagonist SR-141716 on open-field behaviors in male Sprague-Dawley rats. Animals were examined after administration of Delta(9)-THC alone (dose range: 0.3-5.6 mg/kg), SR-141716 alone (dose range: 1-5.6 mg/kg) and the two drugs in combination; injections were given intraperitoneally 30 min prior to testing. There was a dose-related suppression of ambulation (horizontal activity) and rearing (vertical activity) after Delta(9)-THC administration. Co-administration of SR-141716 counteracted this suppression; however, antagonism was only partial for rearing. Interestingly, 1 mg/kg SR-141716 was as effective as 3 and 5.6 mg/kg SR-141716 in this antagonist action. Increasing doses of Delta(9)-THC produced an increase in circling behavior; latency to leave the starting area in the center of the field was significantly elevated by 5.6 mg/kg Delta(9)-THC. Those effects were completely blocked by SR-141716. Grooming and scratching showed a dose-related increase following administration of SR-141716 (1-5.6 mg/kg), which were only partially blocked by co-administration of Delta(9)-THC (3 and 5.6 mg/kg). When given alone, only the highest dose of SR-141716 (5.6 mg/kg) depressed ambulation; rearing and latency were not significantly changed, and circling was absent. Differences in the number of vocalizations, urination and defecation generally did not differ clearly among the treatment conditions. These results may show that SR-141716 is acting as (i) an inverse agonist and/or (ii) that the endogenous cannabinoid system is tonically active under certain conditions. SN - 0091-3057 UR - https://www.unboundmedicine.com/medline/citation/12213538/Interactions_between_the_CB1_receptor_agonist_Delta_9_THC_and_the_CB1_receptor_antagonist_SR_141716_in_rats:_open_field_revisited_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0091305702009383 DB - PRIME DP - Unbound Medicine ER -